{"entity":{"id":"nct07722494","kind":"trial","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of IBI363, Bevacizumab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer is a phase 3 interventional study registered as NCT07722494 by Innovent Biologics (Suzhou) Co. Ltd., with 550 participants planned, started 2026-07-31 and due to reach its primary completion in 2028-10-31. Interventions recorded: IBI363 + bevacizumab, Investigator's choice of therapy. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07722494","url":"https://clinicaltrials.gov/study/NCT07722494"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi363","bevacizumab"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07722494","phase":"3","setting":"A Randomized, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of IBI363 in Combination With Bevacizumab Versus Investigator's Choice of Therapy in Participants With Advanced Colorectal Cancer Who Have Failed or Are Intolerant to Standard Care of Therapy","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","enrolled":550,"outcomes":[]},"route":"/trials/nct07722494/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}